Understand the Treatment Pathway

While KRESLADI™ is a one-time infusion, it is part of a multi-step process. Times will vary per patient.1,2

Patient referral and evaluation

  • The patient is referred to a Qualified Treatment Center by their healthcare provider
  • The Qualified Treatment Center conducts a patient evaluation to confirm KRESLADI treatment is appropriate
  • A benefits investigation is conducted to confirm the patient's insurance coverage and secure prior authorization
  • Prescreening tests are performed before beginning the treatment process

Pre-treatment (~4-6 months)

  • Anti-inflammatory preparation (~2 weeks)1
    • Consider administering ustekinumab prior to mobilization and apheresis and/or prior to KRESLADI infusion
  • Mobilization (6-7 days)1
    • Occurs over 6-7 days at a Qualified Treatment Center. On Days 1-4, patients will receive granulocyte-colony stimulating factor (G-CSF), and on Days 5 and 6 they will receive G-CSF and plerixafor. If needed, G-CSF and plerixafor dosing will be extended to Days 6 and 7
  • Leukapheresis (2-3 days)1,2
    • At a Qualified Treatment Center, the patient's hematopoietic stem cells will be collected and shipped to the manufacturing lab
  • Manufacturing (3-5 months)1,2
    • The patient's hematopoietic stem cells will be modified, quality checked, and cryopreserved, then returned to the Qualified Treatment Center for infusion

Treatment

  • Anti-inflammatory preparation (1-2 weeks) and chemotherapy conditioning (4 days)1
    • One to 2 weeks before KRESLADI infusion, patients will receive a second dose of anti-inflammatory ustekinumab
    • Before KRESLADI infusion, patients will receive myeloablative conditioning with busulfan over 4 days at a Qualified Treatment Center
  • KRESLADI infusion (~10 minutes)1
    • KRESLADI is administered as a single infusion 24-48 hours after the last dose of busulfan at a Qualified Treatment Center. KRESLADI infusion time will vary but will usually be less than 10 minutes

Post-treatment

  • Post-infusion (recovery time may vary)2
    • After infusion, patients will recover at the Qualified Treatment Center until it is determined it is safe for them to go home
  • Long-term follow-up (15 years)1,2
    • After discharge of patients from the Qualified Treatment Center, HCPs will continue to provide care and partner with the patients to create a plan for long-term monitoring and regular follow-ups. Long-term follow-up is an important part of the post-treatment process and should continue for a minimum of 15 years

References: 1. KRESLADI. Prescribing Information. Rocket Pharmaceuticals; 2026. 2. Data on File. KRESLADI Protocol. Rocket Pharmaceuticals; 2024.

Indication and Important Safety Information

INDICATION AND USAGE

KRESLADI is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen (HLA)-matched sibling donor for allogeneic hematopoietic stem cell transplant.

This indication is approved under accelerated approval based on increase in neutrophil CD18 and CD11a surface expression. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Serious Infections

Serious infections have occurred with KRESLADI administration. Increased susceptibility to infections may occur due to administration of myeloablative conditioning prior to KRESLADI infusion.

Monitor patients for signs and symptoms of infection before and after KRESLADI infusion and treat appropriately. Administer prophylactic antimicrobials according to institutional guidelines.

Avoid administration of KRESLADI in patients with active bloodstream infections or other serious, untreated infections.

Any blood products required after KRESLADI infusion should be irradiated.

Veno-Occlusive Disease

Veno-occlusive disease has occurred with KRESLADI treatment. Increased susceptibility to veno-occlusive disease may occur due to administration of myeloablative conditioning prior to KRESLADI infusion. Monitor patients for signs and symptoms of veno-occlusive disease including assessment of liver function tests during the first month following KRESLADI infusion.

Neutrophil Engraftment Failure

Neutrophil engraftment failure may occur after treatment with KRESLADI. Neutrophil engraftment failure is defined as failure to achieve three consecutive absolute neutrophil counts (ANC) ≥ 500 cells/microliter obtained on different days by Day 43 after infusion of KRESLADI. Monitor neutrophil counts until engraftment has been achieved. If neutrophil engraftment failure occurs in a patient treated with KRESLADI, provide rescue treatment with the back-up collection of CD34+ cells.

Delayed Platelet Engraftment

Delayed platelet engraftment may occur after treatment with KRESLADI. Monitor platelet counts and bleeding until platelet engraftment and platelet recovery are achieved.

LVV-Mediated Insertional Oncogenesis

Lentiviral vector (LVV)-mediated insertional oncogenesis may occur after treatment with KRESLADI. Hematologic malignancy is a lifelong risk and patients treated with KRESLADI may develop hematologic malignancy at any time following treatment.

Monitor for hematologic malignancies clinically, and with a complete blood count (with differential) at least annually and integration site analysis as warranted for at least 15 years after treatment with KRESLADI and as clinically indicated. If malignancy is detected in any patient who received KRESLADI, contact Rocket Pharmaceuticals, Inc. at 1-800-982-2410 for reporting and to obtain instructions on collection of samples for testing.

Hypersensitivity Reactions

Hypersensitivity reactions including anaphylaxis may occur with the infusion of KRESLADI. The dimethyl sulfoxide (DMSO) in KRESLADI may cause hypersensitivity reactions which may occur in patients with and without prior exposure to DMSO.

Monitor patients for signs and symptoms of hypersensitivity reactions during and after KRESLADI infusion. If a hypersensitivity reaction occurs, pause infusion if ongoing and manage according to clinical practice.

Anti-retroviral Use

Anti-retroviral medications may interfere with manufacturing of KRESLADI. If a patient requires anti-retrovirals for HIV prophylaxis, mobilization and apheresis of CD34+ cells for KRESLADI manufacturing should be delayed until HIV infection is adequately ruled out. Patients should not take anti-retroviral medications for at least one month prior to mobilization, or for the expected duration required for the elimination of the anti-retroviral medications, and until all cycles of apheresis are completed.

Interference with Serology Testing

Patients who have received KRESLADI are likely to test positive by polymerase chain reaction (PCR) assays for HIV due to LVV provirus insertion resulting in a false-positive test for HIV. Therefore, patients who have received KRESLADI should not be screened for HIV infection using a PCR-based assay.

Blood, organ, tissue, and cell donation

Patients treated with KRESLADI should not donate blood, organs, tissues, or cells for transplantation at any time in the future.

ADVERSE REACTIONS

The most common non-laboratory adverse reactions (≥ 30% of patients) include: mucositis, upper respiratory tract infection, viral infection, febrile neutropenia, skin lesion, nausea/vomiting, rash/dermatitis, pyrexia, device related infection, and skin infection.

The most common laboratory adverse reactions (≥ 30% of patients) include: hemoglobin decreased, platelet count decreased, neutrophil count decreased, leukocyte count decreased, aspartate aminotransferase increased, and alanine aminotransferase increased.

For additional safety information, refer to the full Prescribing Information.

DRUG INTERACTIONS

No formal drug interaction studies have been performed. KRESLADI is not expected to interact with the hepatic cytochrome P-450 family of enzymes or drug transporters.

Vaccines: The safety and effectiveness of immunization with live viral vaccines during or following KRESLADI treatment has not been studied. Vaccination is not recommended during the 6 weeks preceding the start of myeloablative conditioning, and until hematological recovery following treatment with KRESLADI. Where feasible, administer childhood vaccinations prior to myeloablative conditioning for KRESLADI.

Anti-retroviral medications: Patients should not take anti-retroviral medications for at least one month prior to initiating medications for stem cell mobilization and for the expected duration for elimination of the medications, and until all cycles of apheresis are completed. Anti-retroviral medications may interfere with manufacturing of KRESLADI.